Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

(2020) Arvind Dasari et al.   Nature Reviews Clinical Oncology

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma

(2020) Sara W. C. Wen et al.   Cancers

An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate

(2019) Emerson Y. Chen et al.   JAMA Internal Medicine

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

(2019) Lars Henrik Jensen et al.   Cancers

Circulating tumour DNA, a promising biomarker for the management of colorectal cancer

(2018) Shelize Khakoo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

(2018) Jason D. Merker et al.   JOURNAL OF CLINICAL ONCOLOGY

A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology

(2018) Alyson Haslam et al.   EUROPEAN JOURNAL OF CANCER

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

(2017) Ludovic Barault et al.   GUT

Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer

(2017) Karina Dahl Steffensen et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

(2015) J. Tie et al.   ANNALS OF ONCOLOGY

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER